Overview

Icotinib for Completed Resected IB NSCLC With EGFR Mutation

Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well icotinib works in treating patients with completely resected stage IB NSCLC harboring EGFR mutation.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University